Background/Aims: This study evaluated the eradication rate of levofloxacin-containing rescue therapy by treatment duration in patients in whom previous first-and second-line treatment failed. Methods: Fifty-five patients with persistent Helicobacter pylori infection after first-line therapy and second-line therapy were studied in a single referral academic center. We compared the eradication rates by the treatment duration of third-line therapy. Results: Of 55 patients, 12 (21.8%) received rescue therapy for seven days, 24 (43.6%) received rescue therapy for 10 days, and 19 (34.5%) received rescue therapy for 14 days. The eradication rates of therapy with levofloxacin were 65.5% in the 55 enrolled patients and 73.5% in the 49 patients who underwent follow-up testing. In cases where follow-up testing was performed, the eradication rate of 7-day therapy was 58.3%, of 10-day 68.2%, and of 14-day therapy 93.3%. Eradication rate of 14-day therapy was higher than 7-day (p=0.06) and 10-day (p=0.108), but chance could not be ruled out in the difference among groups. Conclusions: This study showed somewhat increasing of H. pylori eradication rate by extending the duration of levofloxacin-containing rescue therapy to 14 days. (Korean J Gastroenterol 2016;68:260-264) 
INTRODUCTION
The eradication rate of the triple standard therapy consisting of proton pump inhibitors (PPI), amoxicillin, and clarithromycin for Helicobacter pylori has been declining due to increased antibiotic resistance incidence. [1] [2] [3] [4] For rescue therapy, bismuth-based quadruple or quinolone-based triple regimens can be considered in persistent H. pylori infections, even after first-line therapy. 5, 6 The Korean College of
Helicobacter and Upper Gastrointestinal Research recommends a bismuth-based quadruple regimen as a second-line therapy in case of failure after clarithromycin-containing triple therapy. 6 If second-line treatment fails to eradicate H. pylori, a tailored treatment based on a bacterial culture test can Values are presented as mean±SD or n (%). *No significant differences between groups (p＞0.05).
be recommended as rescue therapy for persistent infection.
However, culture for antibacterial susceptibility is not widely performed as it is time-consuming and costly. 7 Fluoroquinolone-based therapy has been used as an alternative, but the rate of eradication differs according to dose, form of fluoroquinolone administered, and treatment duration. [8] [9] [10] [11] This study evaluated the eradication rate of a levofloxacin-based regimen as third-line therapy according to treatment duration. 
SUBJECTS AND METHODS

Patients
H. pylori eradication and assessment
Eradication was assessed by the rapid urease test (RUT), the urea breath test (UBT), or histology, four to eight weeks after completing third-line therapy. The RUT using Ponto Dry 
Eradication rate after third-line rescue therapy
Eradication rate was evaluated in all enrolled patients as well as in the patients who underwent follow up tests (RUT, UBT, or histology). To evaluate the efficacy of treatment duration extension, the enrolled patients were assigned to one of three treatment lengths: seven days, 10 days, or 14 days, and patients that underwent testing after eradication were assigned to a subgroup. In addition, tolerability was evaluated based on the number of patients who underwent follow-up testing after completion of third-line therapy.
Statistical analysis
Categorical data were compared among groups using a chi-square or Fisher's exact test. The analyses were carried out using the SPSS for Windows software package (ver. 14.0, released 2005; SPSS Inc., Chicago, IL, USA). Continuous data were presented as means±SDs, and were compared using one-way analysis of variance with Tukey's post-hoc test 
RESULTS
Baseline characteristics
Fifty-five patients treated with a levofloxacin-containing triple rescue regimen due to failure of first-and second-line treatment for H. pylori were selected for review. The mean age of enrolled patients was 57.4±12.1 years, and 69.1% of patients were diagnosed with gastric ulcers, 29.1% with duodenal ulcers, and 1.8% with H. pylori gastritis. Among these patients, 12 (21.8%) received 7-day therapy, 24 (43.6%) received 10-day therapy, and 19 (34.5%) received 14-day therapy. There were no significant group differences in mean age, ratio of gender, or indication of eradication (Table 1) .
Eradication rate and tolerability
In the 55 selected patients, the eradication rate was 65.5% (95% CI, 0.513-0.774). The eradication rate of the 7-day therapy was 58.3% (95% CI, 0.286-0.835), of 10-day therapy 62.5% (95% CI, 0.408-0.805), and of 14-day therapy 73.7% (95% CI, 0.486-0.899) (p=0.625). The eradication rate of the 14-day therapy was not significantly different from that of the 7-day group (p=0.447) ( Table 2 ).
Among the total 55 patients, no patients from the 7-day group, two (8.3%) patients from the 10-day group, and four (21.1%) patients from the 14-day group did not have further visits recorded in their charts and did not undergo the UBT, the RUT, or endoscopy (p=0.206) (Fig. 1) . In the group that underwent later testing, the total eradication rate was 73.5% (95% CI, 0.587-0.846). The eradication rate in the 7-day group was 58.3% (95% CI, 0.286-0.835), in the 10-day group 68.2% (95% CI, 0.451-0.853), and in the 14-day group 93.3% (95% CI, 0.660-0.997) ( Table 2 ). Eradication rates after 14 days of treatment were significantly higher than the 7-day rates (p=0.06), but chance could not be ruled out in the difference between 14 days and 10 days (p=0.108).
DISCUSSION
This retrospective study investigated the eradication rate of levofloxacin-containing triple therapy in clinical practice and assessed the efficacy of different treatment lengths. In patients who underwent follow-up testing, eradication rates were 58.3% for 7-day therapy, 68.2% for 10-day therapy, and 93.3% for 14-day therapy. As treatment duration was extended, the rate of eradication increased; however, this increase was not statistically significant. Unfortunately, the number of patients that did not continue regular exams was highest in the 14-day group. This data suggests that compliance is important to increase the rate of eradication in patients undergoing a levofloxacin-containing triple regimen as rescue therapy. Noh 2016 Conventional triple therapy of clarithromycin, amoxicillin, and PPI is accepted as the first-line treatment choice in many countries, including Korea. 6, 12 However, many factors, including bacterial resistance to antibiotics, poor patient compliance, and cytochrome 2C19 polymorphism, influence the failure of eradication for H. pylori. 13, 14 The eradication rate of conventional triple therapy is reported at less than 80%, and it is not recommended for first-line treatment in areas where the population clarithromycin resistance rate is over 20%. In clinical practice, quinolone-based triple therapy is used widely as rescue therapy. Gisbert et al. 20 reported that bismuth-and levofloxacin-containing quadruple therapy had an eradication rate of >90% as a second rescue therapy, whereas Jeong et al. 21 showed that the eradication rate of levofloxacin-based third-line therapy (500 mg, once or twice per day for 10 days) was 57.1% in 14 patients. The eradication rates of quinolone-based rescue therapy vary according to treatment duration, form and dose of quinolone, and bacterial resistance to quinolone. 11, [22] [23] [24] [25] [26] [27] Resistance to fluoroquinolone is increasing in Korea 28,29 and a 7-day quinolone regimen had a low eradication rate (51.6-69.8%). 30-32 A 10-day quinolone regimen has been used as rescue therapy, [33] [34] [35] [36] [37] but extension of treatment to 14 days seemed to improve the rate of eradication. 26, 38 Our study demonstrated that extension of duration of levofloxacin-based rescue regimen improved the eradication rate, although quinolone resistance is increasing worldwide. [39] [40] [41] Moreover, it is important to note that exposure to quinolone can delay tuberculosis and bacterial resistance diagnosis. 38, 42 In addition, prolonged treatment can result in adverse effects such as metallic taste, nausea, or diarrhea. 35 In this study, follow-up loss increased as treatment duration was extended.
However, we cannot conclude that the loss resulted from adverse events due to extended treatment, as insufficient information was included in the retrospective data we utilized.
This study had several limitations. First, a small number of patients were selected, as only cases with persistent H. pylori after first-and second-line therapy were included. Second, this study provided no details of adverse events associated with extended quinolone treatment. Third, third-line rescue therapy was adopted empirically in a clinical setting and it was not based on cases of bacterial resistance. Additionally, there were no guidelines for treatment duration choice.
Lastly, there is a possibility of eradication rate overestimation, as we considered H. pylori eradicated if negative findings were detected on one or more serial tests.
In conclusion, this study showed a slightly increasing H. pylori eradication rate by extending the duration of levofloxacin-containing rescue therapy to 14 days. However, a large-scale prospective study is required to evaluate the adverse effects related to prolonged treatment duration of quinolones.
